NPCE

16.68

1.36% -0.24

Handel nachbörslich: 16.68

Neuropace Inc (NPCE)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$16.92

Offen:

$17

24-Stunden-Volumen:

108.86K

Relative Volume:

0.53

Marktkapitalisierung:

$568.68M

Einnahmen:

$99.99M

Nettoeinkommen (Verlust:

$-21.47M

KGV:

-25.28

EPS:

-0.6597

Netto-Cashflow:

$-11.34M

1W Leistung:

+5.30%

1M Leistung:

-0.65%

6M Leistung:

+1.15%

1J Leistung:

-5.60%

1-Tages-Spanne:

$16.51

$17.40

1-Wochen-Bereich:

$15.62

$17.40

52-Wochen-Spanne:

$7.5625

$19.60

Neuropace Inc Stock (NPCE) Company Profile

Firmenname

Neuropace Inc

Sektor

Healthcare (1113)

Branche

Medical Devices (143)

Telefon

(650) 237-2700

Adresse

455 N. BERNARDO AVENUE, MOUNTAIN VIEW

Mitarbeiter

220

Twitter

Nächster Verdiensttermin

2026-05-12

Neueste SEC-Einreichungen

NPCE's Discussions on Twitter

Compare NPCE vs ABT, SYK, MDT, BSX, EW

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NPCE Neuropace Inc	16.68	576.87M	99.99M	-21.47M	-11.34M	-0.6597
ABT Abbott Laboratories	86.66	152.25B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	312.95	121.33B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	77.59	100.91B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	57.66	85.88B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	87.56	49.39B	6.30B	1.07B	1.09B	1.8406

Neuropace Inc Stock (NPCE) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-05-28	Eingeleitet	H.C. Wainwright	Buy
2025-01-21	Eingeleitet	UBS	Buy
2024-03-14	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-01-30	Eingeleitet	Leerink Partners	Outperform
2023-11-10	Eingeleitet	Cantor Fitzgerald	Overweight
2023-08-24	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2023-02-22	Eingeleitet	Lake Street	Buy
2022-04-06	Eingeleitet	Wolfe Research	Outperform
2022-01-19	Herabstufung	Wells Fargo	Overweight → Equal Weight
2022-01-07	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2021-11-11	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-08-18	Eingeleitet	Robert W. Baird	Outperform
2021-05-17	Eingeleitet	JP Morgan	Overweight
2021-05-17	Eingeleitet	Morgan Stanley	Overweight
2021-05-17	Eingeleitet	SVB Leerink	Outperform
2021-05-17	Eingeleitet	Wells Fargo	Overweight

Alle ansehen

Neuropace Inc Aktie (NPCE) Neueste Nachrichten

May 25, 2026

NeuroPace (NPCE) CFO receives RSU and stock option awards in Form 4 filing - Stock Titan

May 19, 2026

NeuroPace (NPCE) CMO receives new RSU and stock option awards - Stock Titan

May 19, 2026

NeuroPace (NPCE) CEO receives new RSU and stock option awards - Stock Titan

May 19, 2026

May 18, 2026

Here's why you should add NeuroPace stock to your portfolio now - MSN

May 18, 2026

H.C. Wainwright raises NeuroPace stock price target to $20 on guidance - Investing.com Australia

May 18, 2026

May 15, 2026

NPCE Maintains by HC Wainwright & Co. -- Price Target Raised to $20 - GuruFocus

May 15, 2026

First Light, Mathew Arens report ~2.9M NPCE shares (NPCE) - Stock Titan

May 15, 2026

OrbiMed reports 2,096,527 shares (6.2%) in NeuroPace (NPCE) - Stock Titan

May 15, 2026

H.C. Wainwright Maintains NeuroPace(NPCE.US) With Buy Rating, Raises Target Price to $20 - Moomoo

May 15, 2026

Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $19 - Moomoo

May 15, 2026

NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st

May 15, 2026

May 14, 2026

(NPCE) Movement as an Input in Quant Signal Sets - Stock Traders Daily

May 14, 2026

NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance

May 14, 2026